Promising combo targets early triple-negative breast cancer
NCT ID NCT06604858
First seen Dec 24, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (carboplatin and paclitaxel) can completely eliminate tumors in people with stage I triple-negative breast cancer before surgery. About 31 participants with small, lymph-node-negative tumors will receive the combination, then have surgery to check for any remaining cancer. The main goal is to see how many achieve a complete response, meaning no cancer is found in the breast or lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
-
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, Spain
-
Hospital Arnau de Vilanova de Valencia
Valencia, Spain
-
Hospital Beata María Ana
Madrid, Spain
-
Hospital Cínico San Carlos
Madrid, Spain
-
Hospital Universitari Dexeus
Barcelona, Spain
-
Hospital Universitari Vall D'Hebron
Barcelona, Spain
-
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Hospital Universitario de Navarra
Pamplona, Spain
-
Institut Català d' Oncologia Girona (ICO)
Girona, Spain
Conditions
Explore the condition pages connected to this study.